---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110829"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:08:50.858449+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma reports Q3 net loss $4.0M; Phase 2 ratutrelvir data expected YE 2025

## Summary
- Net loss of $4.0M ($0.34 diluted EPS) vs $8.5M ($1.49) in Q3 2024; R&D and G&A expenses down significantly.
- Cash and equivalents $6.4M at Sept 30, 2025, down from $21.3M at Dec 31, 2024; runway into Q1 2026.
- Acquired key patent from Viriom for $2.6M; intangible assets of $2.6M recorded.
- Ratutrelvir Phase 2 studies dosed; topline data from both studies expected by year-end 2025.
- Iain Dukes permanently appointed CEO, Charles Parker CFO confirmed Oct 6; John Leaman added to board.

## SEC filing metadata
- accession: 0001104659-25-110829
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/0001104659-25-110829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/tm2531045d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110829
- JSON: https://secwatch.observer/filing/0001104659-25-110829.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.